Partnership Forum Opportunities
Collaborate. Network. Optimize.
The live, hands-on AMCP Partnership Forums bring key decision-makers in managed care, integrated care, the pharmaceutical industry, and others together to discuss and collaborate on tactics and strategies to drive efficiencies and outcomes.
Designed to address current market challenges and opportunities, the AMCP Partnership Forums:
- Take a proactive, collaborative approach to solving important issues and challenges
- Represent opportunities for payers, manufacturers, and other stakeholders to work together on common goals and interests, and create actionable results
- Gain consensus on tactics to address key challenges or opportunities, as well as how to remove barriers to improve patient care and optimize value for all stakeholders
- Have high visibility among industry stakeholders and policy-makers
Contact email@example.com to discuss sponsorship opportunities.
2021 Forum Topics
Racial Health Disparities: A Closer Look at Benefit Design
Now more than ever, there is an increased focus on health disparities that occur across a multitude of factors, including socioeconomic status, ethnicity, and race. These health disparities result in avoidable readmissions, reduced quality of care, higher costs, and lower member satisfaction rates. Health care providers, insurers, and managed care pharmacy stakeholders need to identify organizational and system-based solutions to address systemic racial health disparities, including educating Pharmacy & Therapeutics (P&T) committees on racial health equity, gaining a better understanding of best practices that can decrease racial health disparities related to benefit design, and disseminating these best practices.
This forum will identify potential structural issues within the current formulary and benefit design processes that may lead to racial health disparities or inequality and identify viable solutions to reduce racial health disparities in the use of drugs and related therapies.
March 23-24, 2021| Virtual Meeting
Digital Therapeutics 2.0
The role of digital therapies in preventing, managing, and treating medical conditions has evolved greatly in the past few years. They may be used independently or taken in tandem with other therapies to optimize clinical outcomes for patients. Further, patients can self-manage these therapies or they can be managed under the direction of a clinician. As innovative therapies are introduced into the market, challenges with developing evidence-based coverage criteria and tracking utilization have been identified. This forum will outline the key barriers and develop solutions to support the appropriate use and coverage of digital therapeutics in the health care system.
This forum will identify challenges and payer needs related to the evidence for digital therapeutics. The forum will explore the current market space for digital therapeutics including the evidence for the products, place in therapy, monitoring or utilization metrics and barriers that patients face in obtaining therapies.
Aug 31-Sep 1, 2021| The Alexandrian Old Town , Alexandria, VA
Addressing Evidence Gaps in the Expedited Approval Process: Payer Perspectives
Drug development is expensive, time consuming and risky. To address these factors, clinical and regulatory experts in pharmaceutical companies design drug development programs and clinical trials with a focus on meeting the FDA requirements. Especially with drugs approved via expedited pathways, the payer's perspective typically takes a back seat to FDA approval criteria. Further, payer expectations for efficacy and safety, as well as population parameters, can differ from those established to meet FDA stipulations. However, meeting payers’ expectations is critical for patient access and commercial success. Payers increasingly demand demonstration of long-term value, especially for high investment medications or those with a high-risk safety profile. Despite the rigorous steps in the process of drug development, limitations exist due to the difference between FDA approval requirements and payer evidence needs. Participants will outline payer needs, barriers, and solutions for products approved through an expedited approval process regarding evidence for new drug products.
This forum will identify payer needs and current barriers that payer currently face regarding evidence for therapies approved through an expedited approval process. In addition, participants will identify potential solutions to address evidence gaps.
Nov 18-19, 2021 | The Alexandrian Old Town , Alexandria, VA
WORKGROUP - Addressing Barriers to Value-based Payment Models in Integrated Delivery Networks
Collaborate with a group of key stakeholders to address how existing laws are impacting integrated delivery networks (IDNs) and pharmaceutical partnerships. Legal and regulatory requirements (e.g., the Anti-Kickback Statute and Medicaid best price rule) can limit the use of certain strategies that could potentially improve care coordination and patient outcomes. Successful implementation of value-based agreements in IDNs requires a range of complex capabilities. The workgroup will provide examples of real-world challenges and possible solutions that will inform and support efforts for legislative change.
WORKGROUP - Substance Use Disorder: A Focus on Prescription Drug Use
Despite efforts to decrease the use of opioids, challenges remain. AMCP created multiple advisory groups beginning in 2015 recognizing the widespread and devastating nature of the opioid crisis. Over time, these groups addressed access to medications for treatment of substance use disorders and developed a viewpoint document on the importance of co-prescribing naloxone. The purpose of this group is to continue the work of the previous groups and focus on collecting and disseminating guidelines for managed care pharmacists regarding integrated care models and benefit designs that effectively address substance use disorder.